Adial Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period
Adial Pharmaceuticals, Inc. (ADIL) reported Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period of 4.35 million shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod · last filed 2024-04-01
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, shares issued in period for the quarter ending 2023-12-31 was 4.34M shares.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, shares issued in period for the quarter ending 2023-09-30 was 0.00 shares.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, shares issued in period for the quarter ending 2023-06-30 was -175.61K shares.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, shares issued in period for the quarter ending 2023-03-31 was 182.93K shares.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, shares issued in period for fiscal 2023 was 4.35M shares, a 1698.70% increase from fiscal 2022.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, shares issued in period for fiscal 2022 was 241.72K shares, a 354.82% increase from fiscal 2021.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, shares issued in period for fiscal 2021 was 53.15K shares.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, shares issued in period for fiscal 2019 was 93.10K shares, a 97.15% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | 4.34M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | 4.34M shares derived: sum of 2 quarters · filed 2024-04-01 | 4.16M shares derived: sum of 3 quarters · filed 2024-04-01 | 4.35M shares 10-K · filed 2024-04-01 | |||
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-14 | -175.61K shares derived: sum of 2 quarters · filed 2023-11-14 | 7.32K shares 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | -175.61K shares derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-10-30 | 7.32K shares 10-Q/A · filed 2023-10-30 | |||||
| 2023-03-31 | 182.93K shares 10-Q · filed 2023-05-12 | ||||||
| 2022-12-31 | 241.72K shares 10-K · filed 2024-04-01 | 6.04M shares 10-K · filed 2023-03-30 | |||||
| 2021-12-31 | 53.15K shares 10-K · filed 2023-03-30 | ||||||
| 2021-03-31 | 1.01M shares 10-Q · filed 2021-05-17 | ||||||
| 2020-06-11 | 2.82M shares 10-K · filed 2021-03-22 | ||||||
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | 0.00 shares derived: sum of 2 quarters · filed 2020-03-20 | 0.00 shares derived: sum of 3 quarters · filed 2020-03-20 | 93.10K shares 10-K · filed 2020-03-20 | |||
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2019-11-14 | 93.10K shares 10-Q · filed 2019-11-14 | ||||
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | 93.10K shares 10-Q · filed 2019-08-13 | |||||
| 2019-03-31 | 93.10K shares 10-Q · filed 2019-05-13 | ||||||
| 2019-01-31 | 22.31K shares 10-Q · filed 2020-11-13 | ||||||
| 2019-01-22 | 250.00K shares 10-Q · filed 2020-11-13 | ||||||
| 2018-12-31 | 3.27M shares 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |